COMMUNIQUÉS West-GlobeNewswire

Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. [...]
Globus Medical Reports Fourth Quarter and Full Year 2025 Results
24/02/2026
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended [...]
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
24/02/2026
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
24/02/2026
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/02/2026
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and [...]
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
24/02/2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Teva to Present at the Upcoming Investor Conferences in March
24/02/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the [...]
Palvella Therapeutics Announces Proposed Public Offering
24/02/2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
24/02/2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
24/02/2026
OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January [...]
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
24/02/2026
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced [...]
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
24/02/2026
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three [...]
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products [...]
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Aktis Oncology to Present at Upcoming March Investor Conferences
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient [...]

Pages